News|Articles|March 20, 2026

Higher-Dose Semaglutide Approved Under New FDA Accelerated Review Process

Fact checked by: Rose McNulty

Listen

0:00 / 0:00

Key Takeaways

Accelerated approval of semaglutide 7.2 mg establishes a higher-dose, once-weekly GLP-1 RA option for long-term weight reduction under the FDA’s National Priority Voucher framework.
STEP UP (n=1407) demonstrated 18.7% mean weight loss vs 3.9% with placebo at 72 weeks, with 31.2% achieving ≥25% weight reduction.
In STEP UP T2D (n≈512), semaglutide 7.2 mg yielded 13.2% mean weight loss vs placebo, and 21.3% of patients achieved ≥20% weight loss.
Tolerability aligned with established semaglutide profiles, but dysesthesia was notably higher at 7.2 mg (18.9%) than 2.4 mg (4.9%) and placebo (0%) in T2D.
The 7.2 mg dose expands the Wegovy portfolio and may provide an intraclass escalation pathway for inadequate responders to 2.4 mg before proceeding to bariatric surgery.

The FDA approved higher-dose semaglutide 7.2 mg (Wegovy HD), marking the fourth drug approved under the Commissioner's National Priority Voucher pilot program.

Semaglutide 7.2 mg injection (Wegovy HD; Novo Nordisk) was granted FDA approval for the long-term reduction of excess body weight in adults with obesity, or overweight with at least one weight-related condition. Novo Nordisk announced.¹The approval marks the first glucagon-like peptide-1 (GLP-1) receptor agonist approved under the Commissioner's National Priority Voucher pilot program.

The accelerated approval is based on results from the phase 3 STEP UP trial program demonstrating that a once-weekly injection of semaglutide 7.2 mg delivers a mean weight loss of 20.7%.^1-3 A US launch in a single-dose pen is expected in April 2026.¹

“The new FDA is moving with unprecedented efficiency on products that advance national priorities,” FDA Commissioner Martin Makary, MD, MPH, said in a statement.⁴ “Today’s approval is another demonstration of what the FDA can accomplish when we try bold new things.”

The 72-week STEP UP trial (NCT05646706) enrolled 1407 adults with obesity randomly assigned to semaglutide 7.2 mg, 2.4 mg, or placebo plus lifestyle intervention.²The parallel STEP UP T2D trial (NCT05649137) enrolled approximately 512 adults with obesity and type 2 diabetes to the same three treatment arms.³ Updated results from both trials were published in The Lancet Diabetes & Endocrinology in November 2025.^2,3

In STEP UP, semaglutide 7.2 mg produced a mean weight loss of 18.7% compared with a 3.9% weight loss with placebo. Additionally, nearly 1 in 3 participants (31.2%) achieved 25% or greater weight reduction.^1,3 However, gastrointestinal adverse events and dysesthesia were more frequent with the higher dose.

In STEP UP T2D, the 7.2 mg dose achieved 13.2% mean weight loss vs placebo, with 21.3% of patients experiencing weight loss of 20% or greater.^1,3

“Since its launch in 2021, [semaglutide] has transformed the lives of many people living with obesity and helped them achieve meaningful weight loss and important cardiometabolic benefits, including an unprecedented reduction in cardiovascular risk,” said Mike Doustdar, president and CEO of Novo Nordisk, in a statement.¹

The safety and tolerability profile was consistent with prior semaglutide trials and comparable with semaglutide 2.4 mg. During the treatment, gastrointestinal events were the most common adverse events. However, higher incidence of dysesthesia was noted with 7.2 mg (18.9%) versus 2.4 mg (4.9%) and placebo (0%) in STEP UP T2D.³

Semaglutide 7.2 mg joins the existing US Wegovy portfolio, which includes the 25 mg once-daily pill and once-weekly injections at 1.7 mg and 2.4 mg. It is already approved in the EU and UK at the 7.2 mg dose. For patients who do not achieve sufficient weight loss on the 2.4 mg dose, the higher-dose option may offer a meaningful step-up within the same drug class before consideration of surgical intervention.

“Earlier this year, we launched the [semaglutide] pill, and with the accelerated approval of Wegovy HD, we are introducing a new offering for our injectable semaglutide that provides even greater weight loss of approximately 21%,” Doustdar said.¹ "At Novo Nordisk, our goal is to provide innovative therapies that support healthier lives for people living with obesity, and we look forward to launching Wegovy HD to help even more people reach their weight and health goals.”

References

1. Wegovy HD (semaglutide 7.2 mg) approved in the US, providing 20.7% mean weight loss. News Release. Novo Nordisk. March 19, 2026. Accessed March 20, 2026. https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=916516

2. Wharton S, Freitas P, Hjelmesæth J, et al; STEP UP trial group. Once-weekly semaglutide 7.2 mg in adults with obesity (STEP UP): a randomised, controlled, phase 3b trial. Lancet Diabetes Endocrinol. 2025;13(11):949-963. doi:10.1016/S2213-8587(25)00226-8

3. Lingvay I, Bergenheim SJ, Buse JB, et al; STEP UP T2D trial group. Once-weekly semaglutide 7.2 mg in adults with obesity and type 2 diabetes (STEP UP T2D): a randomised, controlled, phase 3b trial. Lancet Diabetes Endocrinol. 2025;13(11):935-948. doi:10.1016/S2213-8587(25)00225-6

4. FDA approves fourth product under National Priority Voucher Program, higher dose semaglutide. News release. FDA. March 19, 2026. Accessed March 20, 2026. https://www.fda.gov/news-events/press-announcements/fda-approves-fourth-product-under-national-priority-voucher-program-higher-dose-semaglutide